TreatSMA

Genetic Alliance UK announces the “Resetting The Model” project

Genetic Alliance UK are working with other charities like TreatSMA on a policy project to improve access to medicines for rare conditions.

Genetic Alliance UK are working on a policy project to improve access to medicines for rare diseases. This project is called Resetting the Model. To inform this project, they are launching a survey to find out the views of patients, carers, patient organisations and industry members  on access to medicines for rare diseases.

The deadline of this survey is Friday 19th April

The survey is open now for the next two weeks and we strongly encourage all parents and carers to participate and share the survey. There is more information on the Genetic Alliance UK website plus a video that explains the aims of the project.

Please support Genetic Alliance UK in their work – click the link below to read more about the project and complete the survey.

Go straight to the survey

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more